Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels

Journal of Hepatology

Volumn 42, Issue 2, 2005, Pages 266-274

  Alberti, Alfredo ^a  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INDIVIDUALIZATION; LIVER BIOPSY; LIVER DISEASE; LIVER HISTOLOGY; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VIRUS REACTIVATION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; LIVER; REFERENCE VALUES; RIBAVIRIN;

EID: 12444261843     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.12.004     Document Type: Review

References (68)

1. J.H. Hoofnagle Hepatitis C: the clinical spectrum of disease Hepatology 26 1997 15S 20S
2. P. Marcellin Hepatitis C: the clinical spectrum of the disease J Hepatol 31 1999 9 16
3. A. Alberti, L. Chemello, and L. Benvegnù Natural history of hepatitis C J Hepatol 31 1999 17 24
4. A.E.T. Yeo, M. Ghany, C. Conry-Cantilena, J.C. Melpolder, D.E. Kleiner, and J.W.K. Shih Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers J Viral Hepatitis 8 2001 256 263
5. A.O. Shakil, C. Conry-Cantilena, H.J. Alter, P. Hayashi, D.E. Kleiner, and V. Tedeschi Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features Ann Intern Med 123 1995 330 337
6. L. Serfaty, J.B. Nousbaum, M.H. Elghouzzi, P. Giral, C. Legendre, and R. Poupon Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test Hepatology 21 1995 725 729
7. C. Conry-Cantilena, M. VanRaden, J. Gibble, J. Melpolder, A.O. Shakil, and L. Viladomiu Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection N Engl J Med 334 1996 1691 1696
8. A. Piton, T. Poynard, F. Imbert-Bismut, L. Khalil, J. Delattre, E. Pelissier, and for the MULTIVIRC Group Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C Hepatology 27 1998 1213 1219
9. C. Puoti HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy J Hepatol 38 2003 529 532
10. M. Prieto, V. Olaso, C. Verdu, J. Cordoba, C. Gisbert, and M. Rayon Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction Hepatology 22 1995 413 417
11. C. Puoti, R. Castellacci, F. Montagnese, S. Zaltron, G. Stornaiuolo, and N. Bergami Histological and virological features and follow-up of HCV carriers with normal aminotransferase levels: the Italian Study of the Asymptomatic C Carriers (ISACC) J Hepatol 37 2002 117 123
12. M. Martinot-Peignoux, N. Boyer, D. Cazals-Hatem, B.-N. Pham, A. Gervais, and V. Le Breton Perspective study of anti-Hepatitis C virus-positive patients with persistently normal serum ALT with or without detectable serum HCV RNA Hepatology 34 2001 1000 1005
13. A. Alberti, L. Benvegnù, S. Boccato, A. Ferrari, and G. Sebastiani Natural history of initially mild chronic hepatitis C Dig Liver Dis 36 2004 646 654
14. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12. Hepatology 2002;36:S3-20
15. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis management and treatment of hepatitis C Hepatology 39 2004 1147 1171
16. J.C. Booth, J. O'Grady, and J. Neuberger Clinical guidelines on the management of hepatitis C Gut 49 2001 I1 I21
17. G.R. Foster, R.D. Goldin, and H.C. Thomas Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis Hepatology 27 1998 209 212
18. M. von Wagner, J.-H. Lee, R. Friedl, B. Kronenberger, C. Sarrazin, and S. Zeuzem Impaired quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels Hepatology 34 2003 454A (abstract 606)
19. S. Zeuzem, M. Diago, E. Gane, R. Reddy, P. Pockros, D. Prati, and for the PEGASYS Study NR16071 Investigator Group Peginterferon alfa-2a (40 KD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 127 2004 1724 1732
20. D. Prati, E. Taioli, A. Zanella, E. della Torre, S. Butelli, and E. del Vecchio Updated definitions of healthy ranges for serum alanine aminotransferase levels Ann Intern Med 137 2002 1 10
21. C. Puoti, A. Magrini, T. Stati, P. Rigato, F. Montagnese, and P. Rossi Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels Hepatology 26 1997 1393 1398
22. G. Montalto, A.L. Zignego, M.I. Ruggeri, C. Giannini, M. Soresi, and M. Monti Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases Dig Dis Sci 42 1997 1703 1707
23. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-61.
24. P. Marcellin, S. Levy, and S. Erlinger Therapy of hepatitis C: patients with normal aminotransferase levels Hepatology 26 1997 133S 136S
25. A. Alberti, F. Noventa, L. Benvegnù, S. Boccato, and A. Gatta Prevalence of liver disease in a population of asymptomatic individuals with hepatitis C virus infection Ann Intern Med 137 2002 961 964
26. A. Alberti, G. Morsica, L. Chemello, D. Cavalletto, F. Noventa, and P. Pontisso Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV Lancet 340 1992 697 698
27. C.K. Hui, A. Monto, T. Belaye, E. Lau, and T.L. Wright Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminase Gut 52 2003 1644 1648
28. M.L. Shiffman, C.A. Stewart, C.M. Hofmann, M.J. Contos, V.A. Luketic, and R.K. Sterling Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histologic and response to interferon therapy J Infect Dis 182 2000 1595 1601
29. A. Erardt, U. Behlen-Wilm, O. Adams, A. Donner, T. Heintges, and D. Haussinger Combination treatment of IFN alpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs Dig Dis Sci 48 2003 921 925
30. A.K. Nutt, H.A. Hassan, J. Lindsey, L.W. Lamps, and J.P. Raufman Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels Am J Med 109 2000 62 64
31. S. Herve, G. Savoye, G. Riachi, M.F. Hellot, O. Goria, and E. Lerebours Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 13 2001 405 500
32. P. Pradat, A. Alberti, T. Poynard, J.-I. Esteban, O. Weiland, and P. Marcellin Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European Collaborative Study Hepatology 36 2002 973 977
33. C. Renou, P. Halfon, S. Pol, P. Cacoub, E. Jouve, and J.P. Bronowicki Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels Gut 51 2002 585 590
34. M.M. Jamal, A. Soni, P.G. Quinn, D.E. Wheeler, S. Arora, and D.E. Johnston Clincial features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States Hepatology 30 1999 1307 1311
35. M.G. Ghany, D.E. Kleiner, H. Alter, E. Doo, F. Khokar, and K. Promrat Progression of fibrosis in chronic hepatitis C Gastroenterology 124 2003 97 104
36. S. Herve, G. Savoye, G. Riachi, M.F. Hellot, O. Goria, and E. Lerebours Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 13 2001 495 500
37. P. Pradat, A. Alberti, T. Poynard, J.-I. Esteban, O. Weiland, and P. Marcellin Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European Collaborative Study Hepatology 36 2002 973 977
38. P. Mathurin, J. Moussalli, J.F. Cadranel, V. Thibault, F. Charlotte, and P. Dumouchel Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity Hepatology 27 1998 868 872
39. M. Persico, E. Persico, R. Suozzo, S. Conte, M. de Seta, and L. Coppola Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels Gastroenterology 118 2000 760 764
40. C.-K. Hui, T. Belaye, K. Montegrande, and T.L. Wright A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase J Hepatol 38 2003 511 517
41. Boccato S, Pistis R, Noventa F, Benvegnù L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. Submitted.
42. S.D. Ryder, and on behalf of the Trent Hepatitis C Study Group Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Gut 53 2004 451 455
43. A. Cividini, C. Rebucci, E. Silini, and M.U. Mondelli Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? Gastroenterology 121 2001 1526 1527
44. M. Ohmiya, J. Hayashi, K. Ueno, N. Furusyo, Y. Sawayama, and Y. Kawakami Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels Dig Dis Sci 45 2000 1953 1958
45. N.C. Tassopoulos, I. Vafiadis, D. Tsantoulas, J. Syrokosta, G. Hatzis, and J.K. DellaDetsima IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: A randomized, controlled study J Interferon Cytokine Res 22 2002 365 369
46. K. Tsuji, K. Yamasaki, M. Yamanishi, M. Kawakami, and S. Shirahama Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study J Gastroenterol Hepatol 16 2001 536 540
47. M.G. Rumi, F. De Filippi, M.F. Donato, E. Del Ninno, and M. Colombo Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough J Viral Hepatol 9 2002 71 74
48. M.G. Rumi, F. De Filippi, C. La Vecchia, M.F. Donato, S. Gallus, and E. Del Ninno Hepatitis C reactivation in patients with chronic infection with genotype 1b and 2c: a retrospective cohort study of 206 untreated patients Gut 2004 (in press)
49. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
50. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.J. Gonçales Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
51. S. Hadziyannis, H.J. Sette, T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
52. A. Alberti Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed? J Hepatol 40 2004 1032 1035
53. B.R. Bacon Treatment of patients with hepatitis C and normal serum aminotransferase levels Hepatology 36 2002 S179 S184
54. A. Rossini, A. Ravaggi, L. Biasi, E. Agostinelli, L. Bercich, and G.B. Gazzola Virological response to interferon treatment in Hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis Hepatology 26 1997 1012 1017
55. N.C. Tassopoulos, I. Vafiadis, D. Tsantoulas, J. Syrokosta, G. Hatzis, and J.K. Delladetsima IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study J Interferon Cytokine Res 22 2002 365 369
56. A. Sangiovanni, R. Morales, G.C. Spinzi, M. Rumi, A. Casiraghi, and R. Ceriani Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study Hepatology 27 1998 853 856
57. S. Mamori, F. Suzuki, T. Hosaka, N. Akuta, T. Someya, and M. Kobayashi Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment J Gastroenterol 39 2004 776 782
58. M. Duvnjak, T. Pavic, L. Virovic, and D. Hrabar Interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal serum alanine aminotransferase values [Croatian] Acta Medica Croatica 57 2003 159 162
59. A. Erhardt, U. Behlen-Wilm, O. Adams, A. Donner, T. Heintges, and D. Haussinger Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs Digest Dis Sci 48 2003 921 925
60. C.K. Hui, A. Monto, T. Belaye, E. Lau, and T.L. Wright Outcomes of interferon a and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases Gut 52 2003 1644 1648
61. A. Mangia, G. Spinzi, O. Vuturo, V. Pazienza, A. Iacobellis, and M. Piattelli Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study Aliment Pharmacol Ther 19 2004 331 337
62. H. Sakugawa, H. Nakasone, T. Nakayoshi, Y. Kawakami, T. Yamashiro, and T. Maeshiro Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT Hepatol Gastroenterol 50 2003 165 169
63. I.M. Jacobson, F. Ahmed, M.W. Russo, E. Lebovics, D.T. Dieterich, and S.P. Esposito Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT Am J Gastroenterol 99 2004 1700 1705
64. F. Hasan, H. Asker, J. Al-Khalib, K. Al-Mekhaizeem, M. Al Shamali, and I. Siddique Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels Digestion 65 2002 127 130
65. S.S. Lee, and M. Sherman Pilot study of interferon-α and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values J Viral Hepatol 8 2001 202 205
66. H.M. Patton, K. Patel, C. Behling, D. Bylund, L.M. Blatt, and M. Vallèe The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients J Hepatol 40 2004 484 490
67. K.Q. Hu, N.L. Kyulo, E. Esrailian, K. Thompson, R. Chase, and D.J. Hillebrand Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States J Hepatol 40 2004 147 154
68. A. Lonardo, L.E. Adinolfi, P. Loria, N. Carulli, G. Ruggiero, and C.P. Day Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease Gastroenterology 126 2004 586 597